Risk of fracture with thiazolidinediones: disease or drugs?
Risk of fracture with thiazolidinediones: disease or drugs?
The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996–2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95% CI 1.06–1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95% CI 1.20–1.31) were similar. In the first (HR = 1.15, 95% CI 1.13–1.18) and second (HR = 1.00, 95% CI 0.96–1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account.
thiazolidinedione, type 2 diabetes mellitus, fracture risk, osteoporosis
450-457
Bazelier, Marloes T.
701385a8-2cb1-4258-88a4-249c3a7f07f5
Vestergaard, Peter
3336d4f1-072c-4b02-935e-a5eca05858e2
Gallagher, Arlene M.
4a77b2c1-c628-47e0-a29c-f726ca3445bc
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, Hubert G. M.
3c6f2841-6825-4de0-b967-1d4aa5498a5d
de Vries, Frank
10245a32-6083-4feb-9d20-7e7db0f358b1
June 2012
Bazelier, Marloes T.
701385a8-2cb1-4258-88a4-249c3a7f07f5
Vestergaard, Peter
3336d4f1-072c-4b02-935e-a5eca05858e2
Gallagher, Arlene M.
4a77b2c1-c628-47e0-a29c-f726ca3445bc
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, Hubert G. M.
3c6f2841-6825-4de0-b967-1d4aa5498a5d
de Vries, Frank
10245a32-6083-4feb-9d20-7e7db0f358b1
Bazelier, Marloes T., Vestergaard, Peter, Gallagher, Arlene M., van Staa, Tjeerd-Pieter, Cooper, Cyrus, Leufkens, Hubert G. M. and de Vries, Frank
(2012)
Risk of fracture with thiazolidinediones: disease or drugs?
Calcified Tissue International, 90 (6), .
(doi:10.1007/s00223-012-9591-8).
(PMID:22488176)
Abstract
The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996–2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95% CI 1.06–1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95% CI 1.20–1.31) were similar. In the first (HR = 1.15, 95% CI 1.13–1.18) and second (HR = 1.00, 95% CI 0.96–1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account.
This record has no associated files available for download.
More information
Published date: June 2012
Keywords:
thiazolidinedione, type 2 diabetes mellitus, fracture risk, osteoporosis
Organisations:
Faculty of Health Sciences
Identifiers
Local EPrints ID: 339042
URI: http://eprints.soton.ac.uk/id/eprint/339042
ISSN: 0171-967X
PURE UUID: 65cfdaf9-8150-494b-b484-6610909a8514
Catalogue record
Date deposited: 22 May 2012 11:19
Last modified: 18 Mar 2024 02:45
Export record
Altmetrics
Contributors
Author:
Marloes T. Bazelier
Author:
Peter Vestergaard
Author:
Arlene M. Gallagher
Author:
Tjeerd-Pieter van Staa
Author:
Hubert G. M. Leufkens
Author:
Frank de Vries
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics